Zoetis Inc. (NYSE:ZTS) Shares Purchased by Biltmore Family Office LLC

Biltmore Family Office LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 8.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,686 shares of the company’s stock after acquiring an additional 126 shares during the quarter. Biltmore Family Office LLC’s holdings in Zoetis were worth $292,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Webster Bank N. A. lifted its stake in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after purchasing an additional 82 shares during the period. Private Wealth Management Group LLC acquired a new stake in shares of Zoetis during the 4th quarter valued at about $33,000. Neo Ivy Capital Management purchased a new position in shares of Zoetis in the 4th quarter valued at about $40,000. LRI Investments LLC acquired a new position in Zoetis in the 1st quarter worth about $43,000. Finally, Blue Bell Private Wealth Management LLC boosted its position in Zoetis by 111.6% during the first quarter. Blue Bell Private Wealth Management LLC now owns 273 shares of the company’s stock worth $46,000 after purchasing an additional 144 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $200.00 target price on shares of Zoetis in a research note on Tuesday, August 27th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research lifted their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $217.11.

Zoetis Stock Down 0.2 %

ZTS stock opened at $191.37 on Wednesday. The company has a market cap of $86.70 billion, a price-to-earnings ratio of 36.87, a PEG ratio of 2.90 and a beta of 0.88. The firm has a 50-day moving average of $181.93 and a two-hundred day moving average of $174.31. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter last year, the business posted $1.41 earnings per share. The firm’s revenue was up 8.3% compared to the same quarter last year. As a group, analysts forecast that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.